Liver disease in transfusion dependent thalassaemia major

Archives of Disease in Childhood

Volumn 86, Issue 5, 2002, Pages 344-347

  Li, C K ^a   Chik, K W ^a   Lam, C W K ^a   To, K F ^a   Yu, S C H ^a   Lee, V ^a   Shing, M M K ^a   Cheung, A Y K ^a   Yuen, P M P ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; FERRITIN; IRON; LIVER ENZYME;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEMOSIDEROSIS; HISTOPATHOLOGY; HUMAN; IRON OVERLOAD; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; BETA-THALASSEMIA; BIOPSY; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; LIVER CIRRHOSIS; MALE; RETROSPECTIVE STUDIES;

EID: 0036255159     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.86.5.344     Document Type: Article

References (23)

1. Survival and disease complications in thalassaemia major
2. Survival and causes of death in thalassaemia major
3. Cirrhosis associated with multiple transfusions in thalassaemia
4. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine
5. Liver iron overload and liver fibrosis in thalassemia
6. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study
7. Iron storage disease
8. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
9. Survival in medically treated patients with homozygous β-thalassemia
10. Evaluation of a prenatal screening procedure for β-thalassaemia carriers in a Chinese population based on the mean corpuscular volume (MCV)
11. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemia patients
12. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions
13. Growth failure and bony changes induced by deferoxamine
14. Hepatic iron concentration and total body iron stores in thalassemia major
15. Hereditary hemochromatosis: Phenotypic expression of the disease
16. Needle liver biopsy in thalassaemia: Analyses of diagnostic accuracy and safety in 1184 consecutive biopsies
17. Iron-chelating therapy and the treatment of thalassemia
18. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia
19. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage
20. Metabolic diseases of the liver
21. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy
22. Evaluation of antibodies to hepatitis C virus in long-term prospective study of posttransfusion hepatitis among thalassemic children